Bitcoin pioneer Charlie Shrem peels back the layers on the lives and backgrounds of the world's most impactful innovators. Centering around intimate narratives, Shrem uncovers a detailed, previously unspoken story of the genesis and evolution of bitcoin, cryptocurrency, artificial intelligence, and the web3 movements. Join Shrem as he journeys through the uncharted territories of tech revolutions, revealing the human side of the stories that shaped the digital world we live in today.
…
continue reading
Content provided by Proactive Investors. All podcast content including episodes, graphics, and podcast descriptions are uploaded and provided directly by Proactive Investors or their podcast platform partner. If you believe someone is using your copyrighted work without your permission, you can follow the process outlined here https://player.fm/legal.
Player FM - Podcast App
Go offline with the Player FM app!
Go offline with the Player FM app!
Lisata Therapeutics CMO explains Haystack Oncology collaboration for pancreatic cancer therapy
MP3•Episode home
Manage episode 430719866 series 2891889
Content provided by Proactive Investors. All podcast content including episodes, graphics, and podcast descriptions are uploaded and provided directly by Proactive Investors or their podcast platform partner. If you believe someone is using your copyrighted work without your permission, you can follow the process outlined here https://player.fm/legal.
Lisata Therapeutics Inc chief medical officer Kristen Buck discusses the company's research collaboration with Haystack Oncology to evaluate the efficacy of certepetide with Proactive's Stephen Gunnion. Buck explained that certepetide is a nine amino acid cyclic peptide designed to target up-regulated receptors on solid tumors, enhancing the delivery of anti-cancer therapies. She highlighted the challenges in treating pancreatic cancer, such as its hostile microenvironment and late-stage detection. Buck detailed the collaboration with Haystack Oncology, emphasizing the use of their minimal residual disease (MRD) technology to detect circulating tumor DNA in blood, which can indicate cancer recurrence or progression. This technology will play a crucial role in Lisata’s ASCEND trial, which is set to report results in the fourth quarter of this year. The ASCEND trial aims to assess the efficacy of certepetide in combination with standard chemotherapy. It includes a second dose of certepetide to determine if increased dosage improves tumor penetration and outcomes. Additionally, Buck discussed the FORTIFIED trial, targeting patients with metastatic pancreatic cancer who have progressed on first-line treatment. This trial evaluates different certepetide dosing regimens in combination with standard chemotherapy. Buck shared insights on the potential impact of these trials, stating, "The goal is to further bathe the hostile tumor microenvironment with certepetide to enhance the active transport pathway, resulting in more intra-tumoral chemotherapy and better outcomes." For more information on Lisata Therapeutics and their innovative cancer treatments, visit Proactive's YouTube channel. Don't forget to give the video a like, subscribe to the channel, and enable notifications for future content. #LisataTherapeutics #Certepetide #PancreaticCancer #CancerResearch #Oncology #HaystackOncology #ClinicalTrials #CancerTreatment #Biotechnology #MedicalResearch #ProactiveInvestors #invest #investing #investment #investor #stockmarket #stocks #stock #stockmarketnews
…
continue reading
605 episodes
MP3•Episode home
Manage episode 430719866 series 2891889
Content provided by Proactive Investors. All podcast content including episodes, graphics, and podcast descriptions are uploaded and provided directly by Proactive Investors or their podcast platform partner. If you believe someone is using your copyrighted work without your permission, you can follow the process outlined here https://player.fm/legal.
Lisata Therapeutics Inc chief medical officer Kristen Buck discusses the company's research collaboration with Haystack Oncology to evaluate the efficacy of certepetide with Proactive's Stephen Gunnion. Buck explained that certepetide is a nine amino acid cyclic peptide designed to target up-regulated receptors on solid tumors, enhancing the delivery of anti-cancer therapies. She highlighted the challenges in treating pancreatic cancer, such as its hostile microenvironment and late-stage detection. Buck detailed the collaboration with Haystack Oncology, emphasizing the use of their minimal residual disease (MRD) technology to detect circulating tumor DNA in blood, which can indicate cancer recurrence or progression. This technology will play a crucial role in Lisata’s ASCEND trial, which is set to report results in the fourth quarter of this year. The ASCEND trial aims to assess the efficacy of certepetide in combination with standard chemotherapy. It includes a second dose of certepetide to determine if increased dosage improves tumor penetration and outcomes. Additionally, Buck discussed the FORTIFIED trial, targeting patients with metastatic pancreatic cancer who have progressed on first-line treatment. This trial evaluates different certepetide dosing regimens in combination with standard chemotherapy. Buck shared insights on the potential impact of these trials, stating, "The goal is to further bathe the hostile tumor microenvironment with certepetide to enhance the active transport pathway, resulting in more intra-tumoral chemotherapy and better outcomes." For more information on Lisata Therapeutics and their innovative cancer treatments, visit Proactive's YouTube channel. Don't forget to give the video a like, subscribe to the channel, and enable notifications for future content. #LisataTherapeutics #Certepetide #PancreaticCancer #CancerResearch #Oncology #HaystackOncology #ClinicalTrials #CancerTreatment #Biotechnology #MedicalResearch #ProactiveInvestors #invest #investing #investment #investor #stockmarket #stocks #stock #stockmarketnews
…
continue reading
605 episodes
All episodes
×Welcome to Player FM!
Player FM is scanning the web for high-quality podcasts for you to enjoy right now. It's the best podcast app and works on Android, iPhone, and the web. Signup to sync subscriptions across devices.